UK markets closed

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7075+0.0100 (+1.43%)
At close: 04:00PM EST
0.7075 0.00 (0.00%)
After hours: 07:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.6975
Open0.6901
Bid0.6905 x 1000
Ask0.7075 x 800
Day's range0.6820 - 0.7075
52-week range0.5600 - 1.5900
Volume448,493
Avg. volume649,220
Market cap107.568M
Beta (5Y monthly)0.69
PE ratio (TTM)N/A
EPS (TTM)-0.6300
Earnings date02 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend date09 Nov 2012
1y target est4.50
  • Simply Wall St.

    Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • Insider Monkey

    Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript

    Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript November 2, 2023 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.18. Operator: Greetings, and welcome to the Vaxart Business Update and Third Quarter 2023 Financial Results Conference Call. A question-and-answer session will follow management’s opening remarks. Individual investors may submit written questions to […]

  • GlobeNewswire

    Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

    Norovirus challenge study topline results indicate the potential of Vaxart’s oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding Clinical proof of concept for the Company’s oral pill vaccine platform now established in two human challenge studies for norovirus and influenza Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business